Cancer therapy‑related cardiac dysfunction and the role of cardiovascular imaging: systemic review and opinion paper from the Working Group on Cardio‑Oncology of the Korean Society of Cardiology

키워드

참고문헌 (60)

1. Quaresma M, "40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011 : a population-based study", Lancet, 385, pp.1206~1218 (2015)
2. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
3. Ng CT, "Advancing cardio-oncology in Asia", Kor Circ J, 53, pp.69~91 (2023)
4. Kim PY, "How to diagnose and manage QT prolongation in cancer patients", JACC CardioOncol, 3, pp.145~149 (2021)
5. Gervaso L, "Venous and arterial thromboembolism in patients with cancer : JACC : CardioOncology state-of-the-art review", JACC CardioOncol, 3, pp.173~190 (2021)
6. Youn JC, "Cardiovascular disease burden in adult patients with cancer : an 11-year nationwide population-based cohort study", Int J Cardiol, 317, pp.167~173 (2020)
7. Lancellotti P, "Cardio-Oncology Services : rationale, organization, and implementation", Eur Heart J, 40, pp.1756~1763 (2019)
8. Dobson R, "BSE and BCOS guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and", or trastuzumab, 2021, pp.3, 1~16
9. Kim H, "Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice : an opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography", J Cardiovasc Ultrasound, 26, pp.1~25 (2018)
10. Lyon AR, "2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association(EHA), the European Society for Therapeutic Radiology and Oncology(ESTRO)and the International Cardio-Oncology Society(IC-OS)", Eur Heart J, 43, pp.4229~4361 (2022)
11. Čelutkienė J, "Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies : a position statement on behalf of the Heart Failure Association(HFA), the European Association of Cardiovascular Imaging(EACVI)and the Cardio-Oncology Council of the European Society of Cardiology(ESC)", Eur J Heart Fail, 22, pp.1504~1524 (2020)
12. Blaes A, "How to follow, manage and treat cardiac dysfunction in patients with Her2+ breast cancer", JACC CardioOncol, 2, pp.661~665 (2020)
13. Tan S, "Immune checkpoint inhibitor therapy in oncology : current uses and future directions : JACC : CardioOncology state-of-the-art review", JACC CardioOncol, 4, pp.579~597 (2022)
14. Dent SF, "How to manage and monitor cardiac dysfunction in patients with metastatic HER2-positive breast cancer", JACC CardioOncol, 4, pp.404~408 (2022)
15. Zhang L, "The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity : JACC : CardioOncology primer", JACC CardioOncol, 3, pp.35~47 (2021)
16. Chung WB, "Cardiovascular complications of novel anticancer immunotherapy : old problems from new agents?", Korean Circ J, 50, pp.743~753 (2020)
17. O’Quinn R, "Cardiac magnetic resonance in cardio-oncology : advantages, importance of expediency, and considerations to navigate pre-authorization", JACC CardioOncol, 3, pp.191~200 (2021)
18. Lopez-Mattei JC, "Cardiac computed tomography in cardio-oncology : JACC : CardioOncology primer", JACC CardioOncol, 3, pp.635~649 (2021)
19. Liu JE, "Strain imaging in cardio-oncology", JACC CardioOncol, 2, pp.677~689 (2020)
20. Sivapackiam J, "PET radiopharmaceuticals for imaging chemotherapy-induced cardiotoxicity", Curr Cardiol Rep, 22, pp.62~ (2020)
21. McCluskey SP, "Imaging of chemotherapy-induced acute cardiotoxicity with 18F-labeled lipophilic cations", J Nucl Med, 60, pp.1750~1756 (2019)
22. Khouri MG, "Cancer therapy-induced cardiac toxicity in early breast cancer : addressing the unresolved issues", Circulation, 126, pp.2749~2763 (2012)
23. Plana JC, "Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", Eur Heart J Cardiovasc Imaging, 15, pp.1063~1093 (2014)
24. Zamorano JL, "2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC)", Eur J Heart Fail, 19, pp.9~42 (2017)
25. Curigliano G, "Management of cardiac disease in cancer patients throughout oncological treatment : ESMO consensus recommendations", Ann Oncol, 31, pp.171~190 (2020)
26. McDonagh TA, "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure", Eur Heart J, 42, pp.3599~3726 (2021)
27. Ezaz G, "Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer", J Am Heart Assoc, 3, pp.e000472~ (2014)
28. Rushton M, "Trastuzumab-induced cardiotoxicity : testing a clinical risk score in a real-world cardio-oncology population", Curr Oncol, 24, pp.176~180 (2017)
29. Arnett DK, "2019 ACC", AHA Guideline on the primary prevention of cardiovascular disease : a report of the American College of Cardiology, J Am Coll Cardiol, pp.2019, 74[DOI]
30. Kim K, "Automated coronary artery calcium scoring in patients with breast cancer to assess the risk of heart disease following adjuvant radiation therapy", Breast, 65, pp.77~83 (2022)
31. Emaus MJ, "Bragatston study protocol : a multicentre cohort study on automated quantification of cardiovascular calcifications on radiotherapy planning CT scans for cardiovascular risk prediction in patients with breast cancer", BMJ Open, 9, pp.e028752~ (2019)
32. Choi JH, "Validation of deep learning-based fully automated coronary artery calcium scoring using non-ECG-gated chest CT in patients with cancer", Front Oncol, 12, pp.989250~ (2022)
33. Kim Y, "Atherosclerosis Imaging Quantitative Computed Tomography(AI-QCT)to guide referral to invasive coronary angiography in the randomized controlled CONSERVE trial", Clin Cardiol, 46, pp.477~483 (2023)
34. Gal R, "Identification of risk of cardiovascular disease by automatic quantification of coronary artery calcifications on radiotherapy planning CT scans in patients with breast cancer", JAMA Oncol, 7, pp.1024~1032 (2021)
35. Jo J, "Cardiovascular outcomes of coronary computed tomography angiography versus functional testing in suspected coronary syndromes : real-world evidence from the nationwide cohort", J Am Heart Assoc, 12, pp.e029484~ (2023)
36. Cha MJ, "Nationwide trends of gatekeeper to invasive coronary angiography in suspected coronary artery disease", Korean Circ J, 52, pp.814~825 (2022)
37. Cho I, "Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals : a 6-year follow-up from the prospective multicentre international CONFIRM study", Eur Heart J, 39, pp.934~941 (2018)
38. Cho I, "Coronary computed tomographic angiography and risk of all-cause mortality and nonfatal myocardial infarction in subjects without chest pain syndrome from the CONFIRM Registry(coronary CT angiography evaluation for clinical outcomes : an international multicenter registry)", Circulation, 126, pp.304~313 (2012)
39. Touyz RM, "Cardiotoxicity with vascular endothelial growth factor inhibitor therapy", NPJ Precis Oncol, 2, pp.13~ (2018)
40. Farkona S, "Cancer immunotherapy : the beginning of the end of cancer?", BMC Med, 14, pp.73~ (2016)
41. Ribas A, "Cancer immunotherapy using checkpoint blockade", Science, 359, pp.1350~1355 (2018)
42. Hu JR, "Cardiovascular toxicities associated with immune checkpoint inhibitors", Cardiovasc Res, 115, pp.854~868 (2019)
43. Salem JE, "Cardiovascular toxicities associated with immune checkpoint inhibitors : an observational, retrospective, pharmacovigilance study", Lancet Oncol, 19, pp.1579~1589 (2018)
44. Lee SH, "Cancer therapyrelated cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin", Cancers(Basel), 14, pp.2320~ (2022)
45. Newick K, "Chimeric antigen receptor T-cell therapy for solid tumors", Mol Ther Oncolytics, 3, pp.16006~ (2016)
46. Ganatra S, "Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma", Circulation, 142, pp.1687~1690 (2020)
47. Fradley MG, "Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor-infiltrating lymphocytes for advanced stage melanoma", J Immunother, 44, pp.86~89 (2021)
48. Lee DW, "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells", Biol Blood Marrow Transpl, 25, pp.625~638 (2019)
49. van Dalen EC, "Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors : a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group", Eur J Cancer, 156, pp.127~137 (2021)
50. Strongman H, "Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers : a population-based cohort study using multiple linked UK electronic health records databases", Lancet, 394, pp.1041~1054 (2019)
51. Armenian SH, "Cardiovascular disease among survivors of adult-onset cancer : a community-based retrospective cohort study", J Clin Oncol, 34, pp.1122~1130 (2016)
52. Armenian SH, "Recommendations for cardiomyopathy surveillance for survivors of childhood cancer : a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group", Lancet Oncol, 16, pp.e123~e136 (2015)
53. Shin J, "Risk of comorbid cardiovascular disease in Korean long-term cancer survivors", Eur J Cancer Care(Engl), 28, pp.e13151~ (2019)
54. Jung MH, "Antihypertensive medication adherence and cardiovascular outcomes in patients with cancer : a nationwide population-based cohort study", J Am Heart Assoc, 12, pp.e029362~ (2023)
55. Jung MH, "Associations between the triglyceride-glucose index and cardiovascular disease in over 150, 000cancer survivors : a population-based cohort study", Cardiovasc Diabetol, 21, pp.52~ (2022)
56. Lee HH, "Changes in physical activity and incident cardiovascular events in cancer survivors", Eur Heart J, 44, pp.4997~5000 (2023)
57. Jeong S, "Estimating risk of cardiovascular disease among long-term colorectal cancer survivors : a nationwide cohort study", Front Cardiovasc Med, 8, pp.721107~ (2022)
58. Oh S, "Increased risk of cardiovascular disease associated with diabetes among adult cancer survivors : a population-based matched cohort study", Eur J Prev Cardiol, 30, pp.670~679 (2023)
59. Yoon DW, "Increased risk of coronary heart disease and stroke in lung cancer survivors : a Korean nationwide study of 20, 458 patients", Lung Cancer, 136, pp.115~121 (2019)
60. So JH, "Risk of cardiovascular disease using Framingham risk score in Korean cancer survivors", Korean J Fam Med, 37, pp.235~241 (2016)

관련 논문AI추천